Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-527 · 1 trial · 14 indications
The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.
| Arm | Type | Description |
|---|---|---|
| CDX-527 | EXPERIMENTAL | Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance. Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase. |
| Name | Type | Description |
|---|---|---|
| CDX-527 | DRUG | CDX-527 is administered by infusion every 2 weeks |
Key Inclusion Criteria: 1. Recurrent, locally advanced or metastatic solid tumor cancer excluding the following: MSI-low colorectal cancer, glioblastoma multiforme, prostate cancer, pancreatic cancer, mucosal and ocular melanoma. 2. Receipt of all standard therapies for the tumor type 3. Measurable...
Top 20 of 84 competitors
CDX-527 is an investigational bispecific antibody being studied for the treatment of non-small cell lung cancer and other advanced solid tumors. It targets PD-L1 and CD27 to potentially enhance the immune response against cancer cells. The drug is currently in Phase 1 clinical development.
CDX-527 targets PD-L1 and CD27. PD-L1 is an immune checkpoint protein that tumors use to evade immune detection, while CD27 is a costimulatory receptor on T cells. By engaging both targets, CDX-527 aims to activate T cells while blocking the PD-L1 pathway.
CDX-527 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CLDX. The company is conducting clinical trials to evaluate the safety and efficacy of this bispecific antibody in patients with advanced malignancies.
CDX-527 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under investigation for potential therapeutic use.
CDX-527 has been studied in one clinical trial with the identifier NCT04440943. This Phase 1 study, titled 'A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,' enrolled 27 participants with various solid tumors, including non-small cell lung cancer. The trial was conducted in the United States and has been completed.
Yes, CDX-527 is a PD-L1xCD27 bispecific antibody. It is designed to simultaneously bind to PD-L1 and CD27. This dual targeting approach is intended to modulate the immune system's response to tumors, potentially offering a novel treatment option for patients with advanced cancers.